Drugs / Ezetimibe
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Nustendi | — | 2020-03-27 | europa.eu ↗ |
| Label expansions (5) | US (FDA) | ZETIA | — | 2006-03-16 – 2012-01-24 | fda.gov ↗ |
| Approved | US (FDA) | ZETIA | — | 2002-10-25 | fda.gov ↗ |
Trials 260 · started per year
today
US approved 2002
EU approved 2020
5
7
8
16
16
24
16
15
9
13
8
3
4
6
12
10
5
5
13
6
11
3
12
6
10
7
10
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT04862260 | Oct 2021 → Jan 2025 overdue | metastatic malignant neoplasm, pancreatic ductal adenocarcinoma | CHU de Quebec-Universite Laval | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02534376 | Sep 2015 → Feb 2019 | prostate cancer | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT02548936 | Apr 2015 → Oct 2016 | atherosclerosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT00863265 | Jun → Oct 2009 | coronary artery disorder, hyperlipoproteinemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 124 trials | ||||||
| Phase 1 | NCT07622433 | Jun → Sep 2026 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06578676 | Jun → Sep 2024 overdue | hyperlipidemia, type 2 diabetes mellitus | Hyundai Pharm | Recruiting | No outcome recorded |
| Phase 1 | NCT06050291 | Jan → Apr 2024 | — | NewAmsterdam Pharma | Completed | No outcome recorded |
| Phase 1 | NCT05372380 | May → Jun 2022 | hyperlipoproteinemia, hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05202405 | Jan → Mar 2022 | hyperlipidemia | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06225635 | Jan → Mar 2022 | hyperlipidemia | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04185090 | Feb → Apr 2020 | hyperlipidemia, hypertensive disorder | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03802526 | Apr → Jul 2019 | — | NVP Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04322266 | Dec 2018 → Feb 2019 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03586037 | Jun → Aug 2018 | hyperlipidemia, hypertensive disorder | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04081844 | May → Jun 2018 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02547402 | Dec 2015 → Jan 2016 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02501200 | Aug → Dec 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02461004 | Jul → Oct 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02730689 | Dec 2014 → Jan 2015 | — | Alvogen Korea | Completed | No outcome recorded |
| Phase 1 | NCT02288338 | Nov 2014 → Feb 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02127320 | Jun → Sep 2014 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02126137 | Oct 2013 → Jan 2016 | chronic hepatitis C virus infection | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| Phase 1 | NCT01723735 | Nov 2012 → Jul 2013 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01597700 | Jan 2012 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01520077 | Jul 2011 → Jan 2015 | alopecia areata | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT00810303 | Mar → Jul 2009 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT00681525 | Apr → Jun 2008 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00652431 | May → Jul 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT07307989 | Aug 2025 → Jul 2029 expected | hyperlipidemia, ischemic stroke | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06437574 | Jul 2024 → Feb 2028 expected | prostate cancer | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05266586 | Mar → Aug 2022 | hyperlipidemia | NewAmsterdam Pharma | Completed | No outcome recorded |
| Phase 2 | NCT04770389 | Feb → May 2021 | hyperlipidemia, hyperlipoproteinemia | NewAmsterdam Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02971033 | Apr 2018 → Mar 2021 | chronic hepatitis C virus infection | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 2 | NCT03051100 | Jan → Jun 2017 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03099278 | Jan → Jun 2017 | hepatitis D virus infection | Ziauddin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03105310 | Jan → Dec 2016 | hepatitis D virus infection | Aga Khan University | Unknown | No outcome recorded |
| Phase 2 | NCT02244944 | Sep 2014 → Sep 2015 | NAFLD1 | Gregory Graf, PhD | Terminated | No outcome recorded |
| Phase 2 | NCT02055976 | Mar 2014 → Jan 2015 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01941836 | Sep 2013 → Oct 2014 | hyperlipoproteinemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01766713 | Jan 2013 → Aug 2014 | metabolic dysfunction-associated steatohepatitis | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT01375764 | Jul 2011 → May 2012 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01218204 | Sep 2010 → Jun 2011 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00405067 | May 2006 → Jan 2007 | hyperlipidemia | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00359281 | Mar 2006 → Nov 2007 | — | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00157482 | Jan 2005 → Dec 2006 | type 2 diabetes mellitus | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT00045812 | Mar 2001 → Apr 2004 | — | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07313124 | Dec 2024 → Nov 2025 | cardiovascular disorder | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT02089867 | Oct 2006 → Aug 2007 | coronary artery disorder | Jose Rocha Faria Neto | Completed | No outcome recorded |
| Phase 2/3 | NCT00566267 | Apr 2006 → Nov 2007 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3103 trials | ||||||
| Phase 3 | NCT07440381 | Sep 2026 → Aug 2027 expected | acute coronary syndrome | Heart Care Foundation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07474649 | Jun 2026 → Jun 2028 expected | coronary atherosclerosis, hyperlipidemia, combined, 2, hyperlipoproteinemia | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07219602 | Dec 2025 → Mar 2028 expected | hyperlipidemia, metabolic syndrome X, type 2 diabetes mellitus | NewAmsterdam Pharma | Recruiting | No outcome recorded |
| Phase 3 | NCT06646354 | Apr → May 2025 overdue | essential hypertension, hyperlipoproteinemia | Hyundai Pharm | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06305559 | May 2024 → Nov 2027 expected | atherosclerosis, coronary artery disorder, hyperlipidemia | NewAmsterdam Pharma | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05930028 | Jul 2023 → Sep 2024 | essential hypertension, hyperlipoproteinemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05657574 | Nov 2022 → Jun 2023 | hyperlipoproteinemia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 3 | NCT05970679 | Aug 2022 → Apr 2023 | hyperlipoproteinemia | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07564726 | Aug 2022 → Feb 2024 | essential hypertension, hyperlipoproteinemia | Celltrion Pharm, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04669041 | Dec 2020 → Jun 2022 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04659070 | Jul 2020 → May 2022 | essential hypertension, hyperlipoproteinemia | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04289649 | Apr → Nov 2020 | hyperlipidemia | Kowa Company, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04289662 | Mar 2020 → Aug 2021 | hyperlipidemia | Kowa Company, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04161001 | Nov 2019 → Nov 2021 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT04584736 | Jun 2019 → Jul 2020 | hyperlipoproteinemia | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT03768427 | May 2019 → Mar 2021 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03872232 | Feb 2019 → Aug 2020 | essential hypertension, hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04017338 | Aug 2018 → Dec 2020 | disease related to solid organ transplantation, hepatitis C virus infection | Jordan Feld | Unknown | No outcome recorded |
| Phase 3 | NCT02715726 | Jul 2016 → Aug 2018 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02741245 | Jun 2016 → Jan 2017 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02748057 | May 2016 → Dec 2017 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02749994 | Apr 2016 → Feb 2017 | hyperlipidemia | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02550288 | Sep 2015 → May 2016 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02460159 | Jun 2015 → Dec 2016 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02451098 | Mar → Oct 2015 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT03288038 | Oct 2014 → Nov 2015 | hyperlipidemia | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03571087 | Sep 2014 → Aug 2015 | hyperlipoproteinemia | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02445352 | Jul 2014 → Jan 2015 | hyperlipoproteinemia | Alvogen Korea | Completed | No outcome recorded |
| Phase 3 | NCT02251847 | Jul 2014 → Jul 2015 | hyperlipidemia | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT02205606 | Jun 2014 → Feb 2015 | hyperlipidemia | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT01849068 | Jun 2013 → Jun 2015 | metabolic syndrome X | Laval University | Completed | No outcome recorded |
| Phase 3 | NCT01154036 | Jul 2010 → Sep 2012 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02205775 | May 2010 → Mar 2012 | coronary artery disorder | G. d'Annunzio University | Terminated | No outcome recorded |
| Phase 3 | NCT00965055 | Sep 2009 → Sep 2011 | coronary artery disorder, low density lipoprotein cholesterol, mild elevation of | University of California, San Diego | Terminated | No outcome recorded |
| Phase 3 | NCT00867165 | May 2009 → Apr 2012 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00862251 | Apr 2009 → Mar 2011 | cardiovascular disorder, diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00782184 | Nov 2008 → Sep 2010 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00783263 | Nov 2008 → May 2010 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00738972 | Jan 2008 → Aug 2010 | hypertensive disorder | Fundación Lindavista del Corazón AC | Terminated | No outcome recorded |
| Phase 3 | NCT00654095 | Dec 2007 → Jun 2009 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00653523 | Dec 2007 → Jun 2009 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00535405 | Nov 2007 → Mar 2009 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00525824 | Aug 2007 → Sep 2008 | atherosclerosis, coronary artery disorder, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00664469 | Aug 2007 → Mar 2010 | hyperlipidemia | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| Phase 3 | NCT00496730 | Jul 2007 → Aug 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00462748 | Mar 2007 → Jun 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00479713 | Feb 2007 → Mar 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00409773 | Jan 2007 → Jul 2008 | hyperlipidemia, metabolic syndrome X | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00395603 | Sep 2006 → Jun 2007 | cardiovascular disorder, diabetes mellitus | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00413972 | Apr → Nov 2006 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00276458 | Feb 2006 → Jan 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00276484 | Feb 2006 → Feb 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00267267 | Jan 2006 → Jan 2007 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00101439 | Nov 2005 → Oct 2006 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00651560 | Nov → Dec 2005 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00129402 | Aug 2005 → Jun 2007 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00423488 | Jul 2005 → Feb 2007 | coronary artery disorder, hyperlipidemia, type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00110435 | May → Dec 2005 | familial hypercholesterolemia, type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00457275 | Apr → Nov 2005 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00395473 | Mar → Nov 2005 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00541697 | Jan → Sep 2005 | type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00132717 | Jan 2005 → Jun 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00349284 | Jan 2005 → ? | hyperlipidemia, combined, 2 | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099996 | Dec 2004 → Dec 2005 | heart disorder, sterol metabolism disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00093899 | Nov 2004 → Sep 2005 | hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092898 | Oct 2004 → Sep 2005 | heart disorder, inherited lipid metabolism disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00195793 | Aug 2004 → ? | hyperlipidemia | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00650819 | Jun 2004 → Feb 2005 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00653445 | Jun 2004 → Jun 2005 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00328523 | Jun 2004 → Jan 2006 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00090298 | Apr → Dec 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00090168 | Jan → Oct 2004 | atherosclerosis, coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00651404 | Jan → Dec 2004 | atherosclerosis, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00651391 | Oct 2003 → Sep 2004 | atherosclerosis, hyperlipidemia | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00171288 | Aug 2003 → Aug 2005 | hyperlipidemia | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00652301 | Jul 2003 → Apr 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092690 | Jun 2003 → Mar 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092612 | May 2003 → Jun 2004 | coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092638 | May 2003 → Jul 2004 | coronary artery disorder, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00650689 | May 2003 → Dec 2004 | atherosclerosis, coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092573 | Apr 2003 → Nov 2004 | hyperlipidemia, hypertriglyceridemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092625 | Mar 2003 → Jul 2004 | coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092599 | Feb 2003 → Jun 2004 | coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092664 | Jan → Sep 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00157911 | Dec 2002 → Oct 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092560 | Dec 2002 → Dec 2003 | hyperlipidemia, hypertriglyceridemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092651 | Sep 2002 → Jun 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092586 | Sep 2002 → Oct 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092833 | Jul 2002 → May 2005 | familial hypercholesterolemia | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00552097 | Jun 2002 → Apr 2006 | atherosclerosis, familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092716 | May 2002 → Apr 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00551447 | Jan 2002 → Mar 2003 | coronary artery disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00551876 | Dec 2001 → Jan 2003 | type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092820 | Feb → Sep 2001 | heart disorder, inherited lipid metabolism disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092807 | Feb → Sep 2001 | heart disorder, inherited lipid metabolism disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03882892 | Feb 2001 → Aug 2002 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03882905 | Jan → Jul 2001 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092677 | Jan 2001 → Apr 2008 | aortic valve stenosis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03885921 | Oct 2000 → Jul 2003 | homozygous familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03882996 | Oct 2000 → Feb 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03884452 | May 2000 → May 2001 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03867318 | Apr 2000 → Nov 2001 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03867110 | Mar 2000 → Jul 2001 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 479 trials | ||||||
| Phase 4 | NCT07508254 | May → Oct 2026 expected | acute coronary syndrome, hyperlipidemia | Punjab Institute of Cardology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06722521 | Jul 2025 → Jun 2032 expected | calcinosis | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06767774 | Apr 2025 → Aug 2029 expected | atherosclerotic cardiovascular disease, diabetes mellitus | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06789432 | Feb → Oct 2025 overdue | hyperlipidemia | Dr. Md. Alimur Reza | Recruiting | No outcome recorded |
| Phase 4 | NCT06784557 | Feb 2024 → Jul 2025 overdue | atherosclerotic cardiovascular disease | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT06186037 | Feb 2024 → Feb 2029 expected | coronary artery disorder, hyperlipidemia | Saint Vincent's Hospital, Korea | Recruiting | No outcome recorded |
| Phase 4 | NCT07442630 | Aug 2023 → Jan 2026 overdue | hyperlipidemia | JW Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06021951 | Aug 2023 → Feb 2024 | — | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05761444 | Jul 2023 → Sep 2024 | atherosclerotic cardiovascular disease | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT05845424 | Jul 2023 → Jun 2029 expected | coronary artery disorder, hyperlipidemia, metabolic syndrome X | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05641753 | Dec 2022 → Jul 2027 expected | type 1 diabetes mellitus | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 4 | NCT05884502 | Sep 2022 → Dec 2023 | hyperlipidemia, ischemic stroke | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05361421 | Jul 2022 → Oct 2027 expected | cardiovascular disorder | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04433533 | Jan 2021 → Jun 2023 | heart disorder, hyperlipidemia | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT04499859 | Oct 2020 → Aug 2026 overdue | myocardial infarction, statin toxicity | Kiyuk Chang, MD,PhD | Recruiting | No outcome recorded |
| Phase 4 | NCT04508907 | Sep 2020 → Nov 2025 overdue | disease related to solid organ transplantation, hepatitis C virus infection | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04369664 | Aug 2020 → Sep 2023 | type 2 diabetes mellitus | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04347434 | Feb 2020 → Nov 2027 expected | acute myocardial infarction, arteriosclerosis disorder | Penza State University | Recruiting | No outcome recorded |
| Phase 4 | NCT04700436 | Jan 2020 → May 2021 | hyperlipidemia, type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03993236 | Sep 2019 → Sep 2021 | ischemic stroke | Keun-Sik Hong | Completed | No outcome recorded |
| Phase 4 | NCT03597412 | Oct 2018 → Aug 2020 | atherosclerotic cardiovascular disease, type 2 diabetes mellitus | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03847506 | Jul 2018 → Dec 2020 | hyperlipidemia | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03434613 | May 2018 → Sep 2019 | NAFLD1, hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT03403556 | Mar 2018 → Oct 2021 | atherosclerotic cardiovascular disease, type 2 diabetes mellitus | Yuhan Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT03494270 | Mar 2018 → Sep 2019 | atherosclerotic cardiovascular disease | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04080310 | Mar 2018 → Jun 2019 | cardiovascular disorder | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03446261 | Feb 2018 → Mar 2019 | hyperlipidemia, type 2 diabetes mellitus | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03217409 | Aug 2017 → Apr 2019 | diabetes mellitus | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04056169 | Jun 2017 → Jul 2019 | acute coronary syndrome, arterial disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02588235 | Oct 2015 → Nov 2017 | coronary artery disorder | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02378064 | May 2015 → Dec 2017 | atherosclerosis, coronary artery disorder | CHEOL WHAN LEE, M.D., Ph.D | Completed | No outcome recorded |
| Phase 4 | NCT02103049 | Apr 2014 → Nov 2015 | hyperlipidemia | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT01950884 | Oct 2013 → Oct 2014 | metabolic dysfunction-associated steatohepatitis | University of Palermo | Unknown | No outcome recorded |
| Phase 4 | NCT02768545 | Jun 2013 → May 2016 | chronic hepatitis C virus infection | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| Phase 4 | NCT01611883 | Jul 2012 → Jan 2014 | — | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT01385631 | Jun 2011 → Jun 2014 | ST-elevation myocardial infarction | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01068093 | Oct 2010 → Oct 2015 | coronary artery disorder | Yokohama City University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01185236 | Sep 2010 → Aug 2011 | type 2 diabetes mellitus | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01043380 | Jan 2010 → Mar 2014 | coronary artery disorder, hyperlipidemia | Kumamoto University | Completed | No outcome recorded |
| Phase 4 | NCT01086020 | Jan 2010 → Dec 2011 | coronary atherosclerosis | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01857843 | Nov 2009 → Nov 2013 | acute coronary syndrome | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00905905 | May → Dec 2009 | myocardial infarction | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT00817843 | Apr 2009 → Sep 2010 | metabolic syndrome X | dr.Frank L.J. Visseren | Completed | No outcome recorded |
| Phase 4 | NCT00843661 | Mar 2009 → Dec 2011 | HIV infectious disease, hyperlipidemia | Ospedale di Circolo - Fondazione Macchi | Unknown | No outcome recorded |
| Phase 4 | NCT00871351 | Feb 2009 → May 2010 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT01008345 | Sep 2008 → Jun 2009 | coronary artery disorder, diabetes mellitus | Hotel Dieu de France Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00701727 | Jun 2008 → Mar 2009 | hyperlipidemia | Radiant Research | Completed | No outcome recorded |
| Phase 4 | NCT00699023 | Jun 2008 → Oct 2009 | hyperlipidemia, type 2 diabetes mellitus | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT00654628 | Aug 2007 → Jul 2009 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00481351 | Jun 2007 → Jan 2010 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00433823 | Jan 2007 → Jan 2008 | atherosclerosis, coronary artery disorder, diabetes mellitus | Abant Izzet Baysal University | Unknown | No outcome recorded |
| Phase 4 | NCT00376246 | Sep 2006 → Apr 2008 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00442897 | Sep 2006 → Oct 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00385658 | Aug 2006 → Mar 2007 | hyperlipidemia | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00423579 | Jul 2006 → Mar 2008 | coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00794677 | Jun 2006 → Feb 2008 | hyperlipoproteinemia | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 4 | NCT01035320 | Jan 2006 → Jun 2012 | diabetes mellitus, impaired renal function disease | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT00652327 | Dec 2005 → Jul 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00157924 | Nov 2005 → Sep 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00166530 | Nov 2005 → Feb 2007 | atherosclerosis | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00166504 | Oct 2005 → Oct 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00319449 | Sep 2005 → Oct 2006 | arteriosclerosis disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00449410 | May 2005 → Oct 2006 | atrial fibrillation | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00202904 | May 2005 → Oct 2006 | coronary artery disorder, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00652847 | May 2005 → May 2007 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00738296 | Apr → Dec 2005 | cardiovascular disorder | Hospital Universitario 12 de Octubre | Completed | No outcome recorded |
| Phase 4 | NCT00652717 | Feb 2005 | cardiovascular disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00466401 | Feb 2005 → Aug 2007 | hyperlipidemia | Ziv Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00189085 | Dec 2004 → Jul 2005 | metabolic syndrome X | UMC Utrecht | Completed | No outcome recorded |
| Phase 4 | NCT00651963 | Sep 2004 → Mar 2005 | inherited lipid metabolism disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00687076 | Apr 2004 → Dec 2010 | peripheral arterial disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00079638 | Apr 2004 → May 2005 | atherosclerosis, coronary artery disorder, diabetes mellitus, hyperlipidemia +1 | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00317993 | Apr → Jul 2004 | — | University of Cologne | Completed | No outcome recorded |
| Phase 4 | NCT00651014 | Jan 2004 → Jun 2006 | atherosclerosis, hyperlipidemia | Organon and Co | Terminated | No outcome recorded |
| Phase 4 | NCT00650663 | Oct 2003 → Sep 2004 | atherosclerosis, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00653796 | Sep 2003 → Aug 2004 | atherosclerosis, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00653835 | Sep 2003 → Aug 2004 | atherosclerosis, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00652444 | Sep 2003 → Aug 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00651274 | Apr 2003 → Aug 2004 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase not applicable29 trials | ||||||
| — | NCT07704918 | Dec 2026 → Dec 2027 expected | melanoma | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| — | NCT07679828 | Jul 2026 → Dec 2029 expected | diabetes mellitus, hyperlipidemia, hypertensive disorder | China Medical University, China | Not yet recruiting | No outcome recorded |
| — | NCT07626840 | Jun 2026 → Jun 2028 expected | acute coronary syndrome | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07524101 | May 2026 → Jan 2031 expected | atherosclerosis, chronic kidney disease, hyperlipidemia | Yonsei University | Recruiting | No outcome recorded |
| — | NCT07359105 | Mar 2026 → Dec 2029 expected | type 2 diabetes mellitus | Sin Gon Kim | Recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06896708 | Aug 2025 → Jul 2027 expected | coronary atherosclerosis | Liu yong | Recruiting | No outcome recorded |
| — | NCT06649240 | Oct 2024 → Sep 2030 expected | ischemic stroke, low density lipoprotein cholesterol, mild elevation of | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT06231966 | Apr 2024 → May 2026 overdue | peripheral arterial disease | Yonsei University | Recruiting | No outcome recorded |
| — | NCT06293417 | Mar 2024 → Feb 2027 expected | hyperlipidemia, type 2 diabetes mellitus | Korea University Anam Hospital | Recruiting | No outcome recorded |
| — | NCT05782777 | Apr 2023 → Dec 2027 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05462262 | Oct 2022 → Jul 2029 expected | coronary atherosclerosis | Chinese Academy of Medical Sciences, Fuwai Hospital | Active not recruiting | No outcome recorded |
| — | NCT05624658 | Sep 2022 → May 2024 | hyperlipidemia | Samara Regional Cardiology Dispensary | Unknown | No outcome recorded |
| — | NCT05368545 | May 2020 → Apr 2024 | coronary artery disorder | Aarhus University Hospital | Completed | No outcome recorded |
| — | NCT03771053 | Jan 2018 → Mar 2019 | coronary artery disorder | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT03044665 | Mar 2017 → Jan 2022 | cerebrovascular disorder, peripheral arterial disease | Yonsei University | Unknown | No outcome recorded |
| — | NCT02942602 | Apr 2014 → May 2016 | hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| — | NCT01584206 | Apr 2012 → Aug 2013 | sitosterolemia | University of Manitoba | Completed | No outcome recorded |
| — | NCT01241097 | Mar → Dec 2010 | — | Federal University of Bahia | Unknown | No outcome recorded |
| — | NCT00634140 | Aug 2009 | acalculous cholecystitis | Indiana University | Withdrawn | No outcome recorded |
| — | NCT00955227 | Jul 2009 → May 2011 | hyperlipidemia | University of Manitoba | Completed | No outcome recorded |
| — | NCT02304926 | Jan 2009 → Dec 2011 | hyperlipidemia | FISABIO Foundation | Completed | No outcome recorded |
| — | NCT00879710 | Aug 2008 → Jul 2013 | hyperlipoproteinemia, type 1 diabetes mellitus, type 2 diabetes mellitus | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT00725829 | Jun 2008 → Jun 2009 | acute coronary syndrome | Jagiellonian University | Unknown | No outcome recorded |
| — | NCT00485121 | Apr 2007 → Mar 2009 | coronary artery disorder, metabolic syndrome X, obesity disorder | Canadian Collaborative Research Network | Completed | No outcome recorded |
| — | NCT00475826 | Apr 2007 → ? | familial hypercholesterolemia | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT00587678 | Jan 2006 → Oct 2009 | peripheral arterial disease | University of Virginia | Completed | No outcome recorded |
| — | NCT00099684 | Nov 2005 → May 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00461968 | Feb 2005 → Apr 2007 | low density lipoprotein cholesterol, mild elevation of | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 126 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT06742853 Background | Dec 2024 → Oct 2025 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06547359 Comparator | Oct → Nov 2024 | — | NewAmsterdam Pharma | Completed | No outcome recorded |
| Phase 1 | NCT04895059 Comparator | Apr 2017 → Jan 2018 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT02289430 Comparator | Dec 2014 → Feb 2015 | — | NVP Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02029625 Comparator | Feb → Mar 2014 | hyperlipidemia | NVP Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT01603758 Comparator | Jan 2014 → Jun 2015 | cholesterol metabolism disease, coronary artery disorder, hyperlipidemia | Richard E. Ostlund Jr., MD | Completed | No outcome recorded |
| Phase 1 | NCT00772551 Comparator | Jun → Aug 2008 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT00621699 Comparator | Sep → Nov 2007 | hyperlipoproteinemia | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT00621101 Comparator | Apr → Jun 2007 | hyperlipoproteinemia | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT00653913 Comparator | Mar → Sep 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT00653276 Comparator | Nov 2003 → Jan 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT00651144 Comparator | Mar → May 2003 | atherosclerosis, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT05795517 Comparator | Apr 2023 → Feb 2024 | hyperlipidemia | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04358432 Background | May 2020 → Feb 2021 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT04173793 Background | Nov 2019 → Sep 2022 | familial hypercholesterolemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT04173403 Background | Nov 2019 → Feb 2023 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT03933293 Background | May 2019 → Mar 2021 | homozygous familial hypercholesterolemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT03531905 Comparator | May 2018 → Jun 2019 | hyperlipidemia, type 2 diabetes mellitus | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02890992 Background | Sep 2016 → Sep 2018 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01890967 Background | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02129231 Comparator | Feb 2012 → Jan 2014 | diabetic polyneuropathy, disorder of defective peroxisome oxidative status | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT01375777 Comparator | Jul 2011 → Mar 2012 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00677248 Background | Apr → Sep 2008 | hyperlipidemia | Karo Bio AB | Completed | No outcome recorded |
| Phase 2 | NCT00559962 Comparator | Oct 2007 → Oct 2008 | hyperlipidemia | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00477204 Comparator | May 2007 → Aug 2010 | hyperlipidemia, type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT00440154 Comparator | Feb → Oct 2007 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 338 trials | ||||||
| Phase 3 | NCT06317051 Comparator | Dec 2024 → Jul 2026 overdue | HIV infectious disease | Kirby Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06450366 Comparator | Jul 2024 → Feb 2025 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT04968509 Background | Mar 2024 → Dec 2027 expected | aortic valve stenosis | Beijing Anzhen Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06005597 Comparator | Mar → Sep 2024 | atherosclerotic cardiovascular disease, familial hypercholesterolemia | NewAmsterdam Pharma | Completed | No outcome recorded |
| Phase 3 | NCT05763875 Comparator | Mar 2023 → Jun 2024 | hyperlipoproteinemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05131997 Comparator | Nov 2021 → Jun 2022 | hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04589351 Comparator | Oct 2020 → May 2022 | diabetic kidney disease, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Unknown | No outcome recorded |
| Phase 3 | NCT04643093 Comparator | Aug 2020 → Aug 2021 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04074551 Comparator | Jul 2019 → Mar 2020 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT03510715 Background | Aug 2018 → Feb 2020 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03510884 Background | May 2018 → Jan 2021 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03337308 Comparator | Oct 2017 → Jun 2018 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03001076 Background | Nov 2016 → Jan 2018 | atherosclerosis, hyperlipidemia, statin toxicity | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02634580 Comparator | Feb 2016 → Aug 2017 | hyperlipoproteinemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02584504 Background | Nov 2015 → Apr 2017 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02476006 Background | Jun 2015 → Apr 2019 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02260648 Comparator | Jan → Nov 2015 | hyperlipidemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT02227784 Comparator | Oct 2014 → Dec 2015 | hyperlipidemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT02023879 Background | Dec 2013 → Oct 2014 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01984424 Comparator | Dec 2013 → Nov 2015 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01420549 Background | Mar 2013 → Nov 2014 | hyperlipidemia | Ache Laboratorios Farmaceuticos S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01763905 Comparator | Jan → Nov 2013 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01763827 Comparator | Jan → Oct 2013 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01763866 Comparator | Jan → Nov 2013 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01730053 Comparator | Nov 2012 → Apr 2014 | hyperlipidemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01730040 Comparator | Oct 2012 → Apr 2014 | hyperlipidemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01709513 Comparator | Sep 2012 → May 2014 | hyperlipidemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01644188 Comparator | Aug 2012 → May 2014 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01644474 Comparator | Jul 2012 → Jul 2013 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01516879 Background | Jan 2012 → Oct 2013 | hyperlipoproteinemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01370590 Comparator | Sep 2011 → Apr 2012 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01370603 Comparator | Sep 2011 → May 2012 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00639158 Comparator | Feb → Oct 2008 | coronary artery disorder, hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00461630 Background | Jan 2007 → Oct 2012 | coronary artery disorder, diabetes mellitus, peripheral arterial disease | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00418834 Comparator | Jan 2007 → Oct 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00271817 Comparator | Dec 2005 → Feb 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00268697 Comparator | Oct 2005 → Jan 2007 | hyperlipoproteinemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00120289 Background | Sep 2005 → Sep 2012 | atherosclerosis, coronary artery disorder, myocardial infarction, stroke disorder | Axio Research. LLC | Terminated | No outcome recorded |
| Phase 443 trials | ||||||
| Phase 4 | NCT07684469 Background | Jun 2026 → Feb 2027 expected | acute coronary syndrome | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07605130 Background | May 2026 → Sep 2028 expected | cognitive disorder, intracranial arteriosclerosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07255820 Comparator | Jan → Mar 2026 overdue | hyperlipoproteinemia, type 2 diabetes mellitus | Bahria University | Recruiting | No outcome recorded |
| Phase 4 | NCT07084259 Comparator | Jul 2025 → Jun 2030 expected | coronary artery disorder | Hanyang University Seoul Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06767345 Comparator | May 2025 → Jan 2028 expected | coronary atherosclerosis | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06381947 Background | May 2024 → Jun 2025 | cardiovascular disorder, cholesterol metabolism disease, hyperlipidemia, statin toxicity | University of Salerno | Unknown | No outcome recorded |
| Phase 4 | NCT05910476 Comparator | May 2023 → Sep 2026 expected | coronary artery disorder, hyperlipidemia | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05579626 Comparator | Mar 2023 → Dec 2030 expected | atherosclerotic cardiovascular disease, prediabetes syndrome | Seung-Whan Lee, M.D., Ph.D. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05661552 Background | Dec 2022 → Feb 2025 | hyperlipoproteinemia | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT05365438 Comparator | Oct 2022 → Dec 2026 expected | atherosclerosis, hyperlipidemia, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05613400 Comparator | Apr 2022 → Dec 2024 | type 2 diabetes mellitus | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT05263778 Comparator | Mar 2022 → Jun 2023 | ST-elevation myocardial infarction | Kaiser Permanente | Unknown | No outcome recorded |
| Phase 4 | NCT04826354 Comparator | Aug 2021 → May 2023 | coronary atherosclerosis | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04659525 Background | Nov 2020 → Nov 2021 | end stage renal failure, hyperlipidemia | Policlinico Casilino ASL RMB | Unknown | No outcome recorded |
| Phase 4 | NCT04397653 Background | May → Nov 2020 | end stage renal failure, hyperlipoproteinemia | Policlinico Casilino ASL RMB | Unknown | No outcome recorded |
| Phase 4 | NCT03750760 Comparator | Jan → Dec 2020 | hyperlipidemia, myocardial infarction | Imperial College London | Withdrawn | No outcome recorded |
| Phase 4 | NCT03543774 Comparator | Jun 2018 → Mar 2020 | chronic kidney disease, hyperlipidemia | Hue University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 4 | NCT03277079 Comparator | Oct → Dec 2017 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT03169985 Comparator | Jul 2017 → Jan 2027 expected | coronary artery disorder | Samsung Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04638400 Comparator | May 2017 → Aug 2021 | atherosclerosis, hyperlipidemia | paresh Dandona | Terminated | No outcome recorded |
| Phase 4 | NCT02984982 Background | Nov 2016 → Jul 2018 | acute coronary syndrome, hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02642159 Comparator | Mar 2016 → Mar 2017 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02772640 Comparator | Mar 2016 → Jan 2019 | hyperlipidemia | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT02682680 Comparator | Jan 2016 → May 2017 | type 2 diabetes mellitus | LMC Diabetes & Endocrinology Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02234544 Comparator | Oct 2014 → Apr 2015 | vitamin D deficiency | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| Phase 4 | NCT01807078 Comparator | Jan 2014 → Dec 2015 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT01490229 Comparator | Jan 2013 → Dec 2014 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT00738985 Comparator | Nov 2009 → Sep 2010 | cardiovascular disorder, hyperlipidemia | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Withdrawn | No outcome recorded |
| Phase 4 | NCT00972829 Comparator | Sep 2009 → Dec 2010 | hyperlipidemia | Bronx VA Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00932620 Comparator | Jun 2009 → Apr 2010 | hyperlipidemia | University of Ioannina | Completed | No outcome recorded |
| Phase 4 | NCT00819403 Comparator | Jan 2009 → Nov 2011 | metabolic syndrome X | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT00861731 Comparator | Nov 2008 → Jul 2009 | chronic kidney disease, hyperlipidemia | Azienda Ospedaliero Universitaria di Sassari | Unknown | No outcome recorded |
| Phase 4 | NCT01384058 Comparator | Nov 2007 → May 2010 | hyperlipidemia, type 2 diabetes mellitus | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 4 | NCT00560170 Comparator | Sep 2007 → Jan 2008 | atherosclerosis | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00762164 Comparator | Mar 2007 → Apr 2009 | hyperlipidemia | Bronx VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00988364 Comparator | Mar 2007 → Feb 2008 | metabolic syndrome X | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00397657 Comparator | Nov 2006 → Aug 2009 | atherosclerosis | Walter Reed Army Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00753883 Comparator | Jul 2006 → May 2008 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00814723 Comparator | Sep 2005 → Sep 2007 | hyperlipoproteinemia | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT00203476 Comparator | May 2005 → Jan 2008 | hyperlipidemia, hyperlipoproteinemia | Tuscaloosa Research & Education Advancement Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00185107 Background | Mar → Oct 2005 | familial hypercholesterolemia | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00651378 Comparator | Sep 2004 → Jun 2005 | atherosclerosis, coronary artery disorder, hyperlipidemia | Organon and Co | Terminated | No outcome recorded |
| Phase 4 | NCT00125593 Comparator | Jun 2003 → Aug 2010 | chronic kidney disease | University of Oxford | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT07615296 Comparator | Jan 2027 → Dec 2029 expected | atherosclerotic cardiovascular disease | Beijing Anzhen Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06930092 Comparator | Aug 2025 → Apr 2028 expected | cardiomyopathy | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT06854523 Comparator | Apr 2025 → Dec 2026 expected | acute myocardial infarction | Yun Dai Chen | Not yet recruiting | No outcome recorded |
| — | NCT05587621 Comparator | Apr 2024 → Apr 2026 overdue | ST-elevation myocardial infarction, low density lipoprotein cholesterol, mild elevation of | Jena University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06096909 Comparator | Nov 2023 → Nov 2025 overdue | acute coronary syndrome | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT04701242 Comparator | Mar 2021 → Dec 2025 overdue | acute myocardial infarction, hyperlipidemia | Cairo University | Recruiting | No outcome recorded |
| — | NCT04626973 Comparator | Jan 2021 → Sep 2025 | atherosclerotic cardiovascular disease | Yonsei University | Completed | No outcome recorded |
| — | NCT04900155 Comparator | Nov 2020 → Nov 2024 | COVID-19, ST-elevation myocardial infarction | Penza State University | Unknown | No outcome recorded |
| — | NCT04656028 Background | Jun 2020 → Jan 2025 overdue | defective apolipoprotein b-100, hypercholesterolemia, autosomal dominant, 3, hypercholesterolemia, autosomal dominant, type B, hypercholesterolemia, familial, 1 +1 | National Medical Research Center for Therapy and Preventive Medicine | Active not recruiting | No outcome recorded |
| — | NCT03355027 Comparator | Nov 2017 → Sep 2019 | atherosclerosis | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT00926055 Comparator | Sep 2011 → Sep 2012 | atherosclerosis | Korea University | Withdrawn | No outcome recorded |
| — | NCT01420328 Comparator | May 2011 → Jul 2015 | — | University at Buffalo | Completed | No outcome recorded |
| — | NCT00908011 Comparator | Jun 2009 → Dec 2014 | HIV infectious disease, hyperlipidemia | University of British Columbia | Completed | No outcome recorded |
| — | NCT00548145 Comparator | Nov 2007 → Oct 2011 | Alzheimer disease, hyperlipidemia | Osaka University | Terminated | No outcome recorded |
| — | NCT00679237 Comparator | Sep 2007 → Dec 2019 | coronary artery disorder | Sorlandet Hospital HF | Completed | No outcome recorded |
| — | NCT00762229 Comparator | Jul 2007 → Sep 2008 | hyperlipidemia | Bronx VA Medical Center | Completed | No outcome recorded |
| — | NCT00474123 Comparator | Jan 2006 → Jan 2009 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01103648 Comparator | Jun 2005 → May 2006 | hyperlipoproteinemia, prediabetes syndrome | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT01424891 Comparator | Apr 2004 → Jul 2006 | type 2 diabetes mellitus | Heidelberg University | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-01-07 | Daiichi Sankyo | Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet daiichisankyo.com ↗ |
| 2017-06-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Zetia® in the United States tevapharm.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 393 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ezetimibe | “Preliminary data are also available data that the combination of statin to ezetimibe (EZE), a cholesterol absorption inhibitor, produces an additional decrease in LDL...” NCT00861731 ↗383“Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fed condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10...” NCT06050291 ↗ “This study will test the safety and effectiveness of SCH-58235 (Ezetimibe) in lowering sitosterol, plant sterol and cholesterol blood levels in patients with homozygous...” NCT00045812 ↗ “A total of 293 patients were randomly assigned into four groups receiving 2 mg pitavastatin, 4 mg pitavastatin, 2 mg pitavastatin/10 mg ezetimibe (K-924 LD), and 4 mg...” PMID 36908150 ↗ Mar 2023 “Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of...” NCT04433533 ↗ “Ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by...” NCT05361421 ↗ “Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual...” PMID 38775910 ↗ May 2024 “All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to...” PMID 22085343 ↗ Nov 2011 “A combination of a lipophilic statin (Atorvastatin, Lipitor), a NPC1L1 inhibitor (Ezetimibe, Ezetrol) and a PCSK9 inhibitor (Evolocumab, Repatha) with chemotherapy in pancreatic cancer” NCT04862260 ↗ “The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation.” NCT06896708 ↗ “Participants received either 10-mg ezetimibe/5-mg atorvastatin (EZE10/ATV5), 10-mg ezetimibe (EZE10), 5-mg atorvastatin (ATV5), or 10-mg atorvastatin (ATV10).” PMID 40251695 ↗ Apr 2025 “The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.” NCT05462262 ↗ “early addition of ezetimibe (EZ) with atorvastatin (AS), prior to reaching the maximally tolerated dose of statin, in very high-risk patients.” PMID 41673582 ↗ Feb 2026 “Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study).” PMID 35307033 ↗ Mar 2022 “Antiplatelet agents and statins will be maintained throughout the study period, and ezetimibe or PCSK9 inhibitors may be added as needed.” NCT06930092 ↗ “Treatment with ezetimibe/simvastatin versus rosuvastatin resulted in a similar improvement of carotid atherosclerotic plaque inflammation” PMID 31426749 ↗ Aug 2019 “To evaluate the efficacy of oral simvastatin + ezetimibe (Vytorin) in treating alopecia areata in subjects 18 years and older.” NCT01520077 ↗ “Pitavastatin 2 mg plus ezetimibe 10 mg, pitavastatin 2 mg, pitavastatin 4 mg plus ezetimibe 10 mg, or pitavastatin 4 mg.” PMID 36241463 ↗ Oct 2022 “Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)” NCT00653913 ↗ “The purpose of this study is to compare the drug interaction of pharmacokinetics of rosuvastatin and ezetimibe.” NCT02289430 ↗ “All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage.” NCT04656028 ↗ “Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days” NCT00652431 ↗ “An FDC of atorvastatin/ezetimibe 5 mg/10 mg or the corresponding individual components was administered” PMID 40206873 ↗ Mar 2025 “Triple oral lipid lowering treatment including high intensity statin, ezetimibe and bembedoic acid” NCT07440381 ↗ “to either "atorvastatin 40 mg daily" or "rosuvastatin 40 mg + ezetimibe 10 mg daily" treatment.” NCT05368545 ↗ “fixed-dose combination of pitavastatin/ezetimibe (K-924 LD: 2 mg/10 mg; K-924 HD: 4 mg/10 mg)” PMID 37722882 ↗ Sep 2023 “The lipid-lowering component will be initiated with rosuvastatin 10 mg plus ezetimibe 10 mg.” NCT07679828 ↗ “ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days” NCT02288338 ↗ “Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks” NCT01420328 ↗ “statins with or without ezetimibe, compared to a high-intensity SOC regimen alone” NCT07684469 ↗ “a fixed-dose combination of ezetimibe/rosuvastatin 10/20 mg, telmisartan 80 mg” PMID 33647189 ↗ Mar 2021 “Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.” NCT02584504 ↗ “Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.” NCT06096909 ↗ “the cholesterol absorption inhibitor Ezetimibe 10 mg and simvastatin 80 mg” NCT00762164 ↗ “patients additionally receive ezetimibe at a dose of 10 mg 1 time / day” NCT04347434 ↗ “treatment with combination of simvastatin 10 mg and ezetimibe 10 mg” NCT01424891 ↗ “tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination” NCT06005597 ↗ “Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)” NCT06225635 ↗ “Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks” NCT03446261 ↗ “Ezetimibe or Fenofibrate at stable dose as background therapy.” NCT02023879 ↗ “the cholesterol-lowering medication ezetimibe are widely used” PMID 36182594 ↗ Sep 2022 “* Month 0-36: Rosuvastatin 10 mg qd + Ezetimibe 10 mg qd” NCT07432516 ↗ “Standard statin-ezetimibe lipid-lowering therapy.” NCT07615296 ↗ “Group 2 - receiving Ezetimibe at a dose of 10 mg” NCT05624658 ↗ “ezetimibe 10 mg combined with rosuvastatin 5 mg” PMID 31727361 ↗ Nov 2019 “Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks” NCT03403556 ↗ “Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)” NCT04081844 ↗ “HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)” NCT03571087 ↗ “Ezetimibe 10mg/Rosuvastatin Ca 20.8mg” NCT04185090 ↗ “Atorvastatin 40mg / Ezetimibe 10mg” NCT05372380 ↗ “Rosuvastatin 10mg/Ezetimibe 10mg” NCT03494270 ↗ “Rosuvastatin 10mg/Ezetimibe 10mg” NCT03597412 ↗ “Ezetimibe (Zetia) 10 mg per day” NCT02244944 ↗ “Atorvastatin/Ezetimibe 40/10mg” NCT05910476 ↗ “Statins ± Ezetimibe” NCT07084259 ↗ “MK0653, ezetimibe” NCT00092807 ↗ “ezetimibe 10mg” NCT06767774 ↗ “Ezetimibe 10mg” NCT02445352 ↗ “Ezetimibe” NCT02205775 ↗ |
| Known as | Acotral | “Bioequivalence study comparing test Acotral® ezetimibe 10 mg tablet manufactured by Laboratorios Phoenix, with a reference comparator Zetia® ezetimibe 10 mg tablet of...” NCT01597700 ↗ |
| Known as | AD-221B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05131997 ↗ |
| Known as | EZE | “The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast...” PMID 30420184 ↗ Oct 20187“Combination of ezetimibe (EZE) with a statin represents an attractive strategy for cholesterol-lowering treatment, as it inhibits the two main sources of cholesterol:...” PMID 17407633 ↗ Apr 2007 “Preliminary data are also available data that the combination of statin to ezetimibe (EZE), a cholesterol absorption inhibitor, produces an additional decrease in LDL...” NCT00861731 ↗ “The purpose of this study was to examine the efficacy and safety of ezetimibe (EZE) coadministered with simvastatin (SIMVA) in a large cohort of African Americans with primary...” PMID 16749654 ↗ May 2006 “To assess if ezetimibe (EZE), a sterol-absorption inhibitor, improves platelet (PLT) count and size relative to its effect on plasma plant sterol (PS) in patients with...” PMID 25444527 ↗ Oct 2014 “triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin” NCT07474649 ↗ “Ezetimibe (EZE) is a cholesterol-lowering drug that inhibits absorption of dietary and biliary cholesterol” PMID 15811480 ↗ Feb 2005 “ezetimibe 10 mg (EZE)” PMID 27206943 ↗ Jan 2016 |
| Known as | Ezetimibe (Zetia) | “Ezetimibe (Zetia)” NCT02244944 ↗ |
| Known as | Ezetrol | “A combination of a lipophilic statin (Atorvastatin, Lipitor), a NPC1L1 inhibitor (Ezetimibe, Ezetrol) and a PCSK9 inhibitor (Evolocumab, Repatha) with chemotherapy in pancreatic cancer” NCT04862260 ↗2“administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15” NCT00810303 ↗ “Ezetrol (Ezetimibe)” NCT00926055 ↗ |
| Known as | MK0653 | “MK0653, ezetimibe / Duration of Treatment: 30 Weeks” NCT00551876 ↗17“MK0653; ezetimibe / Duration of Treatment: 12 weeks” NCT00157911 ↗ “MK0653, ezetimibe / Duration of Treatment: 28 weeks” NCT00092716 ↗ “MK0653, ezetimibe / Duration of Treatment: 27 Weeks” NCT00551447 ↗ “MK0653, ezetimibe / Duration of Treatment: 4 Weeks” NCT00457275 ↗ “MK0653, ezetimibe / Duration of Treatment: 6 Weeks” NCT00395473 ↗ “Ezetimibe (MK0653) 10 mg once daily for 3 years.” NCT00092833 ↗ “MK-0653, ezetimibe” NCT00328523 ↗ “MK0653, ezetimibe” NCT00092820 ↗ “MK0653, ezetimibe” NCT00092625 ↗ “MK0653, ezetimibe” NCT00092898 ↗ “MK0653, ezetimibe” NCT00092612 ↗ “MK0653, ezetimibe” NCT00092599 ↗ “MK0653, ezetimibe” NCT00092638 ↗ “MK0653, ezetimibe” NCT00092560 ↗ “MK0653, ezetimibe” NCT00092586 ↗ “MK0653, ezetimibe” NCT00092573 ↗ |
| Known as | SCH 58235 | “Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)” NCT03884452 ↗4“A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin” NCT00551447 ↗ |
| Known as | Zetia | “Bioequivalence study comparing test Acotral® ezetimibe 10 mg tablet manufactured by Laboratorios Phoenix, with a reference comparator Zetia® ezetimibe 10 mg tablet of...” NCT01597700 ↗5“Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor® (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)” NCT00079638 ↗ “Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients” NCT04508907 ↗ “Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]” NCT01043380 ↗ “Ezetimibe (Zetia) 10 mg per day” NCT02244944 ↗ “ezetimibe \[Zetia\]” NCT00477204 ↗ |
| Action | Inhibit | “Ezetimibe inhibits cholesterol absorption” PMID 23040830 ↗ Sep 2012 |
| Route | Oral | “take a 10-mg pill of ezetimibe daily” NCT00099996 ↗ |
| Target | NPC1L1 | “Recent studies suggest that NPC1L1 (Nieman-Pick C1 Like 1 protein) has a critical role in intestinal cholesterol absorption, being established as a direct target for the action...” NCT00481351 ↗ |